XML 55 R40.htm IDEA: XBRL DOCUMENT
v3.20.2

Collaboration and License Agreements and Supply Agreements - Additional Information (Details) | 1 Months Ended | 3 Months Ended | 9 Months Ended |  |
--- | --- | --- | --- | --- | ---
Apr. 30, 2020 USD ($) | Mar. 31, 2020 USD ($) | Feb. 29, 2020 USD ($) | May 31, 2019 USD ($) | Dec. 31, 2018 USD ($) | Aug. 31, 2018 USD ($) Program | Jul. 31, 2018 Program | Sep. 30, 2017 USD ($) | Aug. 31, 2017 USD ($) Program | Jun. 30, 2016 USD ($) | Mar. 31, 2015 USD ($) | Sep. 30, 2014 USD ($) | May 31, 2014 USD ($) | Sep. 30, 2020 USD ($) | Mar. 31, 2020 USD ($) | Sep. 30, 2019 USD ($) | Sep. 30, 2020 USD ($) | Sep. 30, 2019 USD ($) | Dec. 31, 2019 USD ($) | Jan. 01, 2019 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent payments of embedded derivative and related liability |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 200,000 |  |  | $ 200,000 |  | $ 100,000 |
EMD Serono |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Recognition of up front payment |  |  |  |  |  |  |  |  |  |  |  |  |  | 20,000,000.0 |  |  | 20,000,000.0 |  |  |
Changes in deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 600,000 |  |  |
The Leukemia & Lymphoma Society, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research development and commercialization agreement termination period |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 12 years |  |  |
Research development and commercialization agreement termination description |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | The LLS Agreement terminates upon the earlier of (a) fulfillment of all payment obligations by both parties or (b) 12 years after the effective date. LLS may terminate the LLS Agreement at any time with 60 days’ prior written notice. Either the Company or LLS has the right to terminate the LLS Agreement based on the other party’s uncured material breach. |  |  |
First Cytokine-Derivative Program | Merck Sharp & Dohme Corp |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Extended research term |  | 1 year |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received |  | $ 5,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue, remaining performance obligation, amount |  | 0 |  |  |  |  |  |  |  |  |  |  |  |  | $ 0 |  |  |  |  |
Recognition of up front payment |  | 50,500,000 |  |  |  |  |  |  |  |  |  |  |  |  | 50,500,000 |  |  |  |  |
Transaction price |  | 65,000,000.0 | $ 60,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Constrained variable consideration |  |  | $ 5,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue reallocated property rights |  | 7,800,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Incremental revenue recognized reallocated target programs |  | $ 500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Estimated service period |  | 3 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Incremental revenue recognized |  | $ 1,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Adjustments to transaction price |  | 5,900,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cumulative catch-up in revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,000,000.0 |  |  |  |  |
Development and Manufacturing Services | Vaxcyte, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received | $ 200,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Celgene Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront, nonrefundable payment received |  |  |  |  |  |  |  |  |  |  |  | $ 83,100,000 |  |  |  |  |  |  |  |
Contingent payment received |  |  |  |  |  |  |  |  |  |  | $ 15,000,000.0 |  |  |  |  |  |  |  |  |
Milestone payment received |  |  |  |  |  |  |  |  |  | $ 25,000,000.0 |  |  |  |  |  |  |  |  |  |
Additional milestone payment received |  |  |  |  |  |  |  |  |  | $ 10,000,000.0 |  |  |  |  |  |  |  |  |  |
Option fee payment received |  |  |  |  |  |  |  |  | $ 12,500,000 |  |  |  |  |  |  |  |  |  |  |
Milestone revenue recognized |  |  |  |  | $ 10,000,000.0 |  |  | $ 10,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |
Contingent payments |  |  |  | $ 275,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Option maintenance fee |  |  |  |  |  |  |  |  | $ 12,500,000 |  |  |  |  |  |  |  |  |  |  |
Number of programs advancing through preclinical development | Program |  |  |  |  |  |  |  |  | 4 |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  | $ 8,200,000 |  |  |  |  | 0 |  |  | $ 0 |  | 3,000,000.0 |
Revenue, remaining performance obligation, amount |  |  |  |  |  |  |  |  | 20,700,000 |  |  |  |  |  |  |  |  |  |  |
Celgene Agreement | ASC 606 | Difference between Revenue Guidance in Effect before and after Topic 606 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ (4,500,000)
Celgene Agreement | First Performance Obligation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue, remaining performance obligation, amount |  |  |  |  |  |  |  |  | 8,200,000 |  |  |  |  |  |  |  |  |  |  |
Celgene Agreement | Future Services on Collaboration Joint Steering Committee ("JSC") |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue, remaining performance obligation, amount |  |  |  |  |  |  |  |  | 200,000 |  |  |  |  |  |  |  |  |  |  |
Celgene Agreement | Third Performance Obligation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue, remaining performance obligation, amount |  |  |  |  |  |  |  |  | $ 12,300,000 |  |  |  |  |  |  |  |  |  |  |
Partially Unsatisfied Performance Obligations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total revenue |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,000,000.0 |  | $ 1,000,000.0 | 3,000,000.0 | $ 2,900,000 |  |
Partially Unsatisfied Performance Obligations | EMD Serono |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,500,000 |  | 3,800,000 |  |
Research and Development Services |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total revenue |  |  |  |  |  |  |  |  |  |  |  |  |  | 200,000 |  | 100,000 | 600,000 | 400,000 |  |
Research and Development Services | EMD Serono |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total revenue |  |  |  |  |  |  |  |  |  |  |  |  |  | 300,000 |  | 500,000 | 1,100,000 | 2,200,000 |  |
2018 Celgene Master Services Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Other revenue-related parties |  |  |  |  |  |  |  |  |  |  |  |  |  | 5,900,000 |  | 2,200,000 | 7,100,000 | 3,200,000 |  |
2018 Merck Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received |  |  |  |  |  | $ 60,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  | 23,900,000 |  |  | 23,900,000 |  | 31,900,000 |
Number of research programs | Program |  |  |  |  |  | 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized performance obligation |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 47,100,000 |  |  |  |  |
Transaction price |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 60,000,000.0 |  |  |  |  |
2018 Merck Agreement | ASC 606 | Celgene Corporation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Changes in deferred revenue due to adoption of new accounting policy |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 6,300,000
2018 Merck Agreement | Merck Sharp & Dohme Corp |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received |  |  |  |  |  | $ 60,000,000.0 |  |  |  |  |  |  |  |  |  |  | 60,000,000.0 |  |  |
Number of research programs | Program |  |  |  |  |  |  | 3 |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue from first performance obligation |  |  |  |  |  | 7,300,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Recognition of up front payment |  |  |  |  |  | 47,100,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized performance obligation |  |  |  |  |  | 700,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Extension option fee associated with contingent program |  |  |  |  |  | 4,900,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Increase (decrease) in revenue |  | (5,100,000) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Embedded interest associated with upfront payment |  |  |  |  |  |  |  |  |  |  |  |  |  | 400,000 |  | 800,000 | 1,500,000 | 2,500,000 |  |
FTE Funding Received |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,700,000 |  | 900,000 | 4,200,000 | 2,600,000 |  |
Revenue recognition aggregate milestone payments eligible to receive |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,600,000,000 |  |  |
Milestone method revenue recognition description |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | If one or more products from each of the target programs are developed for non-oncology or a single indication, the Company will be eligible for reduced aggregate milestone payments. In addition, the Company is eligible to receive tiered royalties ranging from mid-single digit to low teen percentages on the worldwide sales of any commercial products that may result from the collaboration. |  |  |
2018 Merck Agreement | Merck Sharp & Dohme Corp | First Target Program |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Increase (decrease) in revenue |  | (6,200,000) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
2018 Merck Agreement | Merck Sharp & Dohme Corp | Second Target Program |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Increase (decrease) in revenue |  | $ 1,100,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
2018 Merck Agreement | Merck Sharp & Dohme Corp | Partially Unsatisfied Performance Obligations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total revenue |  |  |  |  |  |  |  |  |  |  |  |  |  | 6,900,000 |  | 3,800,000 | $ 13,000,000.0 | 10,500,000 |  |
2018 Merck Agreement | Merck Sharp & Dohme Corp | ASC 606 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total interest of unearned revenue |  |  |  |  |  |  |  |  |  |  |  |  |  | 7,300,000 |  |  | 7,300,000 |  |  |
Collaboration Agreement | EMD Serono |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Up-front, nonrefundable and non-creditable payment received |  |  |  |  |  |  |  |  |  |  |  |  | $ 10,000,000.0 |  |  |  |  |  |  |
MDA Agreement | EMD Serono |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  | 0 |  | $ 800,000 |
Up-front, nonrefundable and non-creditable payment received |  |  |  |  |  |  |  |  |  |  |  | $ 10,000,000.0 |  |  |  |  |  |  |  |
Maximum amount eligible to receive for each product developed |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 52,500,000 |  |  |
Milestone Payment and Supply Agreement | EMD Serono |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total revenue |  |  |  |  |  |  |  |  |  |  |  |  |  | 300,000 |  | 600,000 | 2,600,000 | 2,100,000 |  |
Milestone Payment | EMD Serono |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total revenue |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,000,000.0 |  |  | 1,000,000.0 |  |  |
Supply Agreement | Vaxcyte, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total revenue |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 200,000 |  | $ 800,000 | $ 300,000 | $ 1,100,000 |  |
Research Development and Commercialization Agreement | The Leukemia & Lymphoma Society, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment received |  |  |  |  |  | 1,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum contribution in clinical development |  |  |  |  |  | 6,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Initial milestone payment |  |  |  |  |  | 500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum aggregate payment |  |  |  |  |  | $ 19,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition Additional milestone payment received. + References No definition available. + Details
Name: | stro_AdditionalMilestonePaymentReceived
Namespace Prefix: | stro_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Adjustments to transaction price. + References No definition available. + Details
Name: | stro_AdjustmentsToTransactionPrice
Namespace Prefix: | stro_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Changes in deferred revenue. + References No definition available. + Details
Name: | stro_ChangesInDeferredRevenue
Namespace Prefix: | stro_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaboration agreement up-front, nonrefundable, non-creditable payment received. + References No definition available. + Details
Name: | stro_CollaborationAgreementUpFrontNonrefundableNonCreditablePaymentReceived
Namespace Prefix: | stro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Constrained variable consideration. + References No definition available. + Details
Name: | stro_ConstrainedVariableConsideration
Namespace Prefix: | stro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Contingent payment received. + References No definition available. + Details
Name: | stro_ContingentPaymentReceived
Namespace Prefix: | stro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Contingent payments. + References No definition available. + Details
Name: | stro_ContingentPayments
Namespace Prefix: | stro_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Convertible preferred stock warrant liability fair value. + References No definition available. + Details
Name: | stro_ConvertiblePreferredStockWarrantLiabilityFairValue
Namespace Prefix: | stro_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Cumulative catch-up in revenue. + References No definition available. + Details
Name: | stro_CumulativeCatchUpInRevenue
Namespace Prefix: | stro_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Embedded interest associated with upfront payment. + References No definition available. + Details
Name: | stro_EmbeddedInterestAssociatedWithUpfrontPayment
Namespace Prefix: | stro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Estimated service period. + References No definition available. + Details
Name: | stro_EstimatedServicePeriod
Namespace Prefix: | stro_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Extended research term. + References No definition available. + Details
Name: | stro_ExtendedResearchTerm
Namespace Prefix: | stro_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Extension option fee associated with contingent program. + References No definition available. + Details
Name: | stro_ExtensionOptionFeeAssociatedWithContingentProgram
Namespace Prefix: | stro_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition FTE funding received. + References No definition available. + Details
Name: | stro_FTEFundingReceived
Namespace Prefix: | stro_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Increase (decrease) in revenue. + References No definition available. + Details
Name: | stro_IncreaseDecreaseInRevenue
Namespace Prefix: | stro_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Incremental revenue recognized. + References No definition available. + Details
Name: | stro_IncrementalRevenueRecognized
Namespace Prefix: | stro_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Incremental revenue recognized reallocated target programs. + References No definition available. + Details
Name: | stro_IncrementalRevenueRecognizedReallocatedTargetPrograms
Namespace Prefix: | stro_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Initial milestone payment. + References No definition available. + Details
Name: | stro_InitialMilestonePayment
Namespace Prefix: | stro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Maximum aggregate payment. + References No definition available. + Details
Name: | stro_MaximumAggregatePayment
Namespace Prefix: | stro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Maximum amount eligible to receive for each product developed. + References No definition available. + Details
Name: | stro_MaximumAmountEligibleToReceiveForEachProductDeveloped
Namespace Prefix: | stro_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Maximum contribution in clinical development. + References No definition available. + Details
Name: | stro_MaximumContributionInClinicalDevelopment
Namespace Prefix: | stro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone method revenue recognition description. + References No definition available. + Details
Name: | stro_MilestoneMethodRevenueRecognitionDescription
Namespace Prefix: | stro_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Milestone payment received. + References No definition available. + Details
Name: | stro_MilestonePaymentReceived
Namespace Prefix: | stro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Upfront, nonrefundable payment received. + References No definition available. + Details
Name: | stro_NonrefundableUpfrontPaymentReceived
Namespace Prefix: | stro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of programs advancing throughout preclinical development. + References No definition available. + Details
Name: | stro_NumberOfProgramsAdvancingThroughoutPreclinicalDevelopment
Namespace Prefix: | stro_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of research programs. + References No definition available. + Details
Name: | stro_NumberOfResearchPrograms
Namespace Prefix: | stro_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Option fee payment received. + References No definition available. + Details
Name: | stro_OptionFeePaymentReceived
Namespace Prefix: | stro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Option maintenance fee. + References No definition available. + Details
Name: | stro_OptionMaintenanceFee
Namespace Prefix: | stro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Research development and commercialization agreement termination description. + References No definition available. + Details
Name: | stro_ResearchDevelopmentAndCommercializationAgreementTerminationDescription
Namespace Prefix: | stro_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Research development and commercialization agreement termination period. + References No definition available. + Details
Name: | stro_ResearchDevelopmentAndCommercializationAgreementTerminationPeriod
Namespace Prefix: | stro_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References No definition available. + Details
Name: | stro_RevenueFirstPerformanceObligation
Namespace Prefix: | stro_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Revenue performance obligation amounts recognized in revenues. + References No definition available. + Details
Name: | stro_RevenuePerformanceObligationAmountsRecognizedInRevenues
Namespace Prefix: | stro_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue reallocated property rights. + References No definition available. + Details
Name: | stro_RevenueReallocatedPropertyRights
Namespace Prefix: | stro_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue recognition aggregate milestone payments eligible to receive. + References No definition available. + Details
Name: | stro_RevenueRecognitionAggregateMilestonePaymentsEligibleToReceive
Namespace Prefix: | stro_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue recognition of up-front payment amount. + References No definition available. + Details
Name: | stro_RevenueRecognitionOfUpFrontPaymentAmount
Namespace Prefix: | stro_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Revenue recognition under milestone method. + References No definition available. + Details
Name: | stro_RevenueRecognitionUnderMilestoneMethod
Namespace Prefix: | stro_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Transaction price. + References No definition available. + Details
Name: | stro_TransactionPrice
Namespace Prefix: | stro_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Unearned revenue. + References No definition available. + Details
Name: | stro_UnearnedRevenue
Namespace Prefix: | stro_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Upfront payment received. + References No definition available. + Details
Name: | stro_UpfrontPaymentReceived
Namespace Prefix: | stro_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 55 -Paragraph 27 -URI http://asc.fasb.org/extlink&oid=121551570&loc=SL49130611-203046-203046 + Details
Name: | us-gaap_ContractWithCustomerRefundLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585 + Details
Name: | us-gaap_IncreaseDecreaseInDeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Reflects the sum of all other revenue and income realized from sales and other transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party during the period. + References No definition available. + Details
Name: | us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 235 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=stro_EMDSeronoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=stro_TheLeukemiaLymphomaSocietyIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=stro_FirstCytokineDerivativeProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=stro_MerckSharpAndDohmeCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=stro_DevelopmentAndManufacturingServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=stro_VaxcyteIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=stro_CelgeneAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=stro_FirstPerformanceObligationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=stro_FutureServicesOnCollaborationJointSteeringCommitteeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=stro_ThirdPerformanceObligationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=stro_PartiallyUnsatisfiedPerformanceObligationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=stro_ResearchAndDevelopmentServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=stro_TwoThousandEighteenCelgeneMasterServicesAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=stro_TwoThousandEighteenMerckAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=stro_CelgeneCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=stro_FirstTargetProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=stro_SecondTargetProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=stro_PartiallyUnsatisfiedPerformanceObligationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=stro_MDAAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=stro_MilestonePaymentAndSupplyAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=stro_MilestonePaymentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=stro_SupplyAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=stro_ResearchDevelopmentAndCommercializationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |